332593

(2-Hydroxypropyl)-β-cyclodextrine

average M_w ~1,380

• Synonyme(s) : (2-Hydroxypropyl)-beta-cyclodextrin
• Numéro CAS: 128446-35-5
• Numéro CE : 420-920-1
• Code UNSPSC : 12352302
• ID de substance PubChem : 24859909
• Nomenclature NACRES : NA.22

Propriétés

• Forme: powder
• Activité optique: [α]26/D +139°, c = 1 in H₂O
• Poids mol.: average M_w ~1,380
• Ampleur du marquage: 0.6 molar substitution
• Pf: 278 °C (dec.)
• Chaîne SMILES: CC(O)COCC1OC2OC3C(COCC(C)O)OC(OC4C(COCC(C)O)OC(OC5C(COCC(C)O)OC(OC6C(COCC(C)O)OC(OC7C(COCC(C)O)OC(OC8C(COCC(C)O)OC(OC1C(OCC(C)O)C2OCC(C)O)C(OCC(C)O)C8OCC(C)O)C(OCC(C)O)C7OCC(C)O)C(OCC(C)O)C6OCC(C)O)C(OCC(C)O)C5OCC(C)O)C(OCC(C)O)C4OCC(C)O)C(OCC(C)O)C3OCC(C)O
• InChI: 1S/C63H112O42/c1-22(64)8-85-15-29-50-36(71)43(78)57(92-29)100-51-30(16-86-9-23(2)65)94-59(45(80)38(51)73)102-53-32(18-88-11-25(4)67)96-61(47(82)40(53)75)104-55-34(20-90-13-27(6)69)98-63(49(84)42(55)77)105-56-35(21-91-14-28(7)70)97-62(48(83)41(56)76)103-54-33(19-89-12-26(5)68)95-60(46(81)39(54)74)101-52-31(17-87-10-24(3)66)93-58(99-50)44(79)37(52)72/h22-84H,8-21H2,1-7H3/t22?,23?,24?,25?,26?,27?,28?,29-,30-,31?,32?,33?,34?,35?,36?,37-,38?,39-,40+,41+,42+,43?,44+,45?,46+,47+,48+,49+,50+,51+,52-,53-,54-,55-,56-,57+,58-,59+,60-,61-,62-,63-/m1/s1
• Clé InChI: ODLHGICHYURWBS-RYJYQAAZSA-N

Description

Description générale

(2-Hydroxypropyl)-β-cyclodextrin (HP-β-CD) is a beta-cyclodextrin and hydroxyalkyl derivative and is widely used as a chiral solvent, phase transfer catalyst, and host molecule in organic synthesis. HP-β-CD can form inclusion complexes with guest molecules, which can help enhance the solubility, stability, and bioavailability of the guest molecule. It is an alternative to α-, β- and γ-cyclodextrin and exhibits a higher water solubility. HP-β-CD is commonly used as a drug solubilizer.

Application

HP-β-CD can be used:

• As an additive in the separation of amino acids and lactic acids based on the coordination interactions between Cu²⁺ ions and analytes.
• As a chiral selector in capillary electrophoresis, enabling the robust separation of diastereomeric derivatives of aspartic acid for analysis.
• As a reagent to improve water solubility and anti-proliferative activity of pyrazolo[3,4-d] pyrimidines.
• As formulation vehicle. It increases water solubility of the drug for successful delivery of medical agents to a biological system.
• To increase the solubility of ropivacaine (RVC) upon complexation, which in turn enhances the pharmacological activity of RVC.
• To increase the aqueous solubility of naproxen (NAP) in presence of polyvinylpyrrolidone (PVP).
• As a template in the synthesis of hollow spherical copper sulfide nanoparticle assemblies.

La solubilité des médicaments lipophiles augmente de manière linéaire avec la concentration en hydroxypropyl-β-cyclodextrine (HPCD) en solution aqueuse du fait de la formation d′un complexe HBC-médicament. Ce complexe de type invité-hôte, où le médicament se loge dans la cavité non polaire de la HPCD, améliore la solubilité du médicament. Les solutions peuvent être lyophilisées pour obtenir des poudres facilement solubles. Non toxique chez le lapin et la souris.

Informations sur la sécurité

• Code de la classe de stockage: 13 - Non Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 1
• Point d'éclair (°F): >752.0 °F
• Point d'éclair (°C): > 400 °C
• Équipement de protection individuelle: Eyeshields, Gloves, type N95 (US)